Charles Piller

Well, it's a great question, and there's no simple answer to that. But I think part of what I'm trying to do with the book that I wrote is to bring these sets of questions to a broad audience. And let me just say briefly that we're talking about a lot of scientific issues, and there are technical aspects to these, some of which are described in the book. But this is a book that is a narrative.

Well, it's a great question, and there's no simple answer to that. But I think part of what I'm trying to do with the book that I wrote is to bring these sets of questions to a broad audience. And let me just say briefly that we're talking about a lot of scientific issues, and there are technical aspects to these, some of which are described in the book. But this is a book that is a narrative.

It's a narrative investigation that tells the story of how these problems occurred by the story of people who are involved with these matters and their personal journeys. So I tried to make it accessible to people of, you know, all kinds of people who might be interested in these for themselves or families. What do you hope that they get from reading the book?

It's a narrative investigation that tells the story of how these problems occurred by the story of people who are involved with these matters and their personal journeys. So I tried to make it accessible to people of, you know, all kinds of people who might be interested in these for themselves or families. What do you hope that they get from reading the book?

It's a narrative investigation that tells the story of how these problems occurred by the story of people who are involved with these matters and their personal journeys. So I tried to make it accessible to people of, you know, all kinds of people who might be interested in these for themselves or families. What do you hope that they get from reading the book?

One, I'd like there to be better public awareness and action on improving scientific institutions to shake them out of their complacency and lassitude in dealing with these very important issues of authenticity and consistency. and correct scientific information in the science literature.

One, I'd like there to be better public awareness and action on improving scientific institutions to shake them out of their complacency and lassitude in dealing with these very important issues of authenticity and consistency. and correct scientific information in the science literature.

One, I'd like there to be better public awareness and action on improving scientific institutions to shake them out of their complacency and lassitude in dealing with these very important issues of authenticity and consistency. and correct scientific information in the science literature.

And when I say how important that is, what I mean is that when the scientific literature is polluted with bad ideas, it skews thinking, it skews directions of research, and ultimately, As Matthew Schrag, who is an important character in my book and an incredibly principled scientist, has said, you can't cure a disease with fake science. Biology doesn't care.

And when I say how important that is, what I mean is that when the scientific literature is polluted with bad ideas, it skews thinking, it skews directions of research, and ultimately, As Matthew Schrag, who is an important character in my book and an incredibly principled scientist, has said, you can't cure a disease with fake science. Biology doesn't care.

And when I say how important that is, what I mean is that when the scientific literature is polluted with bad ideas, it skews thinking, it skews directions of research, and ultimately, As Matthew Schrag, who is an important character in my book and an incredibly principled scientist, has said, you can't cure a disease with fake science. Biology doesn't care.

And so what we want is more rapid progress. So that, number one, is I hope that we can clean some things up and create an attitude of... kind of thoughtful attention to this problem by the institutions of science, by scientists, and by the journals. So that's number one. Number two is I think people who are living with Alzheimer's, either as patients

And so what we want is more rapid progress. So that, number one, is I hope that we can clean some things up and create an attitude of... kind of thoughtful attention to this problem by the institutions of science, by scientists, and by the journals. So that's number one. Number two is I think people who are living with Alzheimer's, either as patients

And so what we want is more rapid progress. So that, number one, is I hope that we can clean some things up and create an attitude of... kind of thoughtful attention to this problem by the institutions of science, by scientists, and by the journals. So that's number one. Number two is I think people who are living with Alzheimer's, either as patients

or as family members who are taking care of folks who have Alzheimer's, need a little bit of background in order to press for better action and better results in a field that has been very disappointing over the last 30 years. So let me give you an example that might be a direct answer to your question about what people say to their doctors.

or as family members who are taking care of folks who have Alzheimer's, need a little bit of background in order to press for better action and better results in a field that has been very disappointing over the last 30 years. So let me give you an example that might be a direct answer to your question about what people say to their doctors.

or as family members who are taking care of folks who have Alzheimer's, need a little bit of background in order to press for better action and better results in a field that has been very disappointing over the last 30 years. So let me give you an example that might be a direct answer to your question about what people say to their doctors.

So a couple of new drugs have been approved recently for Alzheimer's dementia. And these are drugs that attack these amyloid proteins that we've been talking about. And the first one is called Lekembe. That's the one that's been on sale for more than a year now. And

So a couple of new drugs have been approved recently for Alzheimer's dementia. And these are drugs that attack these amyloid proteins that we've been talking about. And the first one is called Lekembe. That's the one that's been on sale for more than a year now. And

So a couple of new drugs have been approved recently for Alzheimer's dementia. And these are drugs that attack these amyloid proteins that we've been talking about. And the first one is called Lekembe. That's the one that's been on sale for more than a year now. And